Sapient Capital LLC Lowers Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

Sapient Capital LLC lowered its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 2.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 136,077 shares of the company’s stock after selling 3,269 shares during the quarter. Sapient Capital LLC’s holdings in Elanco Animal Health were worth $1,429,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of ELAN. CoreCap Advisors LLC acquired a new position in shares of Elanco Animal Health during the fourth quarter worth about $29,000. NBC Securities Inc. purchased a new stake in Elanco Animal Health in the 1st quarter valued at approximately $40,000. Parallel Advisors LLC increased its position in Elanco Animal Health by 92.2% during the 1st quarter. Parallel Advisors LLC now owns 3,860 shares of the company’s stock worth $41,000 after purchasing an additional 1,852 shares during the period. Versant Capital Management Inc increased its position in Elanco Animal Health by 65.9% during the 1st quarter. Versant Capital Management Inc now owns 4,382 shares of the company’s stock worth $46,000 after purchasing an additional 1,740 shares during the period. Finally, Jones Financial Companies Lllp raised its stake in shares of Elanco Animal Health by 95.6% during the 4th quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after buying an additional 2,059 shares in the last quarter. Hedge funds and other institutional investors own 97.48% of the company’s stock.

Analysts Set New Price Targets

ELAN has been the topic of a number of analyst reports. Barclays decreased their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating on the stock in a research report on Thursday, March 6th. Morgan Stanley lowered their price target on shares of Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 26th. UBS Group reduced their price objective on shares of Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Stifel Nicolaus boosted their price objective on shares of Elanco Animal Health from $15.00 to $16.00 and gave the stock a “buy” rating in a report on Monday, May 19th. Four research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Stock Down 0.6%

ELAN opened at $14.19 on Friday. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a market cap of $7.05 billion, a price-to-earnings ratio of 35.48, a PEG ratio of 2.50 and a beta of 1.67. Elanco Animal Health Incorporated has a one year low of $8.02 and a one year high of $18.55. The business’s fifty day moving average is $11.27 and its two-hundred day moving average is $11.44.

Elanco Animal Health (NYSE:ELAN) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.37 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.06. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. Elanco Animal Health had a return on equity of 6.78% and a net margin of 4.60%. The business’s revenue was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.34 EPS. Analysts anticipate that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.